Talk:Pharmacotherapy (journal)

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Academic Journals

	This article is within the scope of WikiProject Academic Journals, a collaborative effort to improve the coverage of Academic Journals on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Academic JournalsWikipedia:WikiProject Academic JournalsTemplate:WikiProject Academic JournalsAcademic Journal articles
See WikiProject Academic Journals' writing guide for tips on how to improve this article.

Sources for expansion in Further reading

Latest comment: 9 years ago1 comment1 person in discussion

The Further reading section contains a number of articles that could be used to expand this article. "A ghost in the machine" deals with the ghost writing of articles on rofecoxib by sponsor (drug companies) employess exposed by Ross et al.^[1] This was a notable controversy, Pharmacotherapy was identified in Ross et al. - - MrBill3 (talk) 16:50, 29 December 2014 (UTC)Reply

References

^ Ross, JS; Hill, KP; Egilman, DS; Krumholz, HM (April 2008). "Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation". JAMA. 299 (15): 1800–12. doi:10.1001/jama.299.15.1800. PMID 18413874.

Add topic

[1] Ross, JS; Hill, KP; Egilman, DS; Krumholz, HM (April 2008). "Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation". JAMA. 299 (15): 1800–12. doi:10.1001/jama.299.15.1800. PMID 18413874.

[1]